

Mumbai, May 26, 2014

Wockhardt FY14 Net Sales at Rs.4830 crore and PAT at Rs.841 crore

	Q4-FY14		Q4-FY13	FY14		FY13
	Jan - Mar 2014		Jan - Mar 2013	Apr - Mar 2014		
	Rsc	Gwth Y-O-Y	Rsc	Rsc	Gwth Y-O-Y	
Sales	1,038	-30%	1,486	4,830	-14%	5,610
R&D	101	-22%	130	403	29%	313
R&D % to Sales	9.7%		8.7%	8.3%		5.6%
Operating Profit	122	-78%	546	980	-53%	2,091
Op. Profit Margins %	11.8%		36.7%	20.3%		37%
Profit After Tax	75	-78%	335	841	-47%	1,594
PAT Margins	7.2%		22.6%	17.4%		28%
EPS	6.8		30.6	76.7	-47%	145.6

Wockhardt Limited, the Pharmaceutical and Biotechnology major, reported its 4th quarter and full year results for Financial Year 2014, today.

Financial year 2013-14

Consolidated revenue for FY 13-14 was Rs.4830 crore and Profit After Tax was at Rs.841 crore which represents 17.4% of Profit After Tax Margins

Research expenses stood at Rs.403 crores for FY 13-14 representing 8.3% of sales and including capital expenditure is at 9.3% of sales

Wockhardt filed 17 new product applications with USFDA during the year.

Net Debt to Equity now stands at 0.05 compared to 0.36 in the previous year.

PRESS RELEASE



Wockhardt Limited
| Wockhardt Towers |
| Bandra Kurla Complex |
| Mumbai 400 051 | India |
| Tel.: +91-22-2653 4444 |
| www.wockhardt.com

Quarter ended 31st March 2014

Consolidated revenue for the quarter was Rs.1038 crore and Profit After Tax was at Rs.75 crore which represents 7.2% of Profit After Tax Margins.

The company increased its Research spend significantly and the same is now at 9.7% to sales at Rs.101 crores and including capital expenditure is at 10.7% to sales for the quarter.

Wockhardt filed 10 new product applications with USFDA during the quarter taking cumulative filings pending approval to 62.

Wockhardt also filed for 134 patents during the quarter taking the cumulative filings to 2001 and has been granted 17 patents during the quarter taking the cumulative patents granted to 259.

Capex

Capital expenditure of Rs.359 crore was incurred during FY 13-14.

Business Highlights

Wockhardt's International Business contributed 79% of the total Revenues during the year.

Wockhardt's US business declined by 26% for FY 13-14 and contributed 45% of the Global Revenues for Wockhardt in FY 13-14.

The UK business recorded a growth of 3% in FY 13-14. Wockhardt launched 4 new products in UK Market for FY 13-14

The Irish market recorded a decline of 15% in FY 13-14. Wockhardt launched 12 new products in Irish Market during FY 13-14

The India business grew by 2% in FY 13-14, while the Emerging Markets business (Including India) declined by 3% in FY 13-14.

Wockhardt launched 26 new products in Domestic Market in FY 13-14

PRESS RELEASE



Wockhardt Limited
| Wockhardt Towers |
| Bandra Kurla Complex |
| Mumbai 400 051 | India |
| Tel.: +91-22-2653 4444 |
| www.wockhardt.com

Wockhardt Limited has organized a conference call and webcast for investors and analysts on Tuesday, May 27, 2014 from 11.00am – 12.00pm IST. The details of the webcast and conference call are as follows:

Timing	: 11:00 am IST on Tuesday, May 27, 2014
¹Webcast link	: http://cs3-ipresent.choruscall.com/FlexPresenter
¹Webcast user-name	: <your name>
¹Webcast passcode	: 3475118
²Conference dial-in Primary number	: +91 22 67465887 / +91 22 39600687
Hong Kong Local Access Number	: 800 964 448
Singapore Local Access Number	: 800 101 2045
UK Local Access Number	: 0 808 101 1573
USA Local Access Number	: 1 866 746 2133
Replay Facility	: Available until June1, 2014 on + 91 22 3065 1212 Play Back ID – 190813# Replay will be available 2 hours after the call ends

¹For viewing the presentation while it is being discussed by the management

²For audio and the question and answer session

About Wockhardt:

Wockhardt is a highly technology intensive global pharmaceutical and biotechnology company. It's multi-disciplinary and innovative R&D programmes globally, are strongly focused on creating Intellectual Properties. It has 3 research centres globally and manufacturing facilities across India, USA, UK and Ireland. Wockhardt has a significant presence in USA, Europe and India, with 79% of its global revenues coming from international businesses. With a large pool of Patents and Intellectual Property knowhow, Wockhardt is home to 607 scientists, of whom 80 are doctorates. In all, Wockhardt has 259 Patents granted worldwide. In biotechnology research, it has built competent 'Concept to Market' capability in all facets of development and manufacture of recombinant biopharmaceuticals. Wockhardt boasts of a multi-ethnic workforce of more than 8,600 people from 21 different nationalities.